Relief Therapeutics and InveniAI Sign Strategic Collaboration Agreement to Identify New Product Development Opportunities Using Artificial Intelligence

GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“ Relief “), announced today that it has signed a collaboration agreement (the” Collaboration “) with InveniAI LLC (“ InveniAI “), a US-based company that has pioneered the application of artificial intelligence and machine learning in the biopharmaceutical industry and other industries, to identify promising drug candidates to treat rare and specialized diseases.

Under the terms of the collaboration, InveniAI will use its proprietary platform for identifying potential pharmaceutical product opportunities using its Pharma Big Data innovation lab (“ Platform “), consisting of (i) its proprietary platform AlphaMeld (R), a cloud-based Artificial Intelligence (“ TO THE “) a platform that uses proprietary neural networks based on machine learning and deep learning to identify product opportunities in therapeutic areas, (ii) its cross-functional teams in its integrated center of excellence, and (iii) domain expertise, to generate new pharmaceutical opportunities and the related development path for the development of such concepts.

As part of the collaboration, it is expected that InveniAI will use its platform to browse the volume of data for all drugs approved by regulatory agencies and their associated active ingredients (active pharmaceutical ingredient (“ API “)) to identify potential indications of rare and specialized diseases for development and commercialization by Relief (“ Product concepts InveniAI will seek to prioritize key product concepts, associated diseases, scientific packages and evidence to support potential drug development opportunities by Relief. Relief anticipates that InveniAI’s platform will complement existing capabilities of Relief. its wholly owned subsidiary APR Applied Pharma Research SA in research and development and drug reformulation.Based on products developed by InveniAI, Relief hopes to develop proprietary versions of existing drugs and protect those drugs with intellectual property at long term and defensible patent claims.

Under the terms of the collaboration, Relief will pay InveniAI upfront fees, success milestones, and marketing royalties for the entire development program. Additional financial details were not disclosed.

“We believe that the addition of InveniAI’s AI-based capabilities will significantly complement our existing drug development efforts. AI is becoming an increasingly important tool for identifying and screening new drug projects and Relief intends to take full advantage of this promising technology, ”said Raghuram (Ram) Selvaraju, President of Relief. “In partnership with InveniAI, we are accessing decades of expertise that have already led to successful drug re-innovation (for example, vilazodone for the treatment of depression and dexmedetomidine for the treatment of agitation) and a further -proven form which has been the basis of several partnerships with established companies. We believe our work with InveniAI could generate multiple promising additions to our pipeline that may represent capital-efficient, cost-effective, and mitigated product development approaches. By focusing on optimizing existing approved APIs, we hope to ensure well-established clinical safety and tolerance for the product concepts initially identified, thus giving us a good start in the further development of new uses for these drugs. In our view, this approach will allow us to quickly and efficiently execute the innovation that brings relief to patients with severe and debilitating conditions. “


Relief primarily focuses on clinical stage programs based on molecules with a history of clinical trials and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100 (TM) (aviptadil), a synthetic form of vasoactive intestinal peptide (VIP), is in advanced clinical testing in the United States for the treatment of respiratory impairment due to COVID- 19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a collaboration and license agreement with Acer Therapeutics for the development and commercialization of ACER-001 globally. ACER-001 is a proprietary, taste-masked, immediate-release powder formulation of sodium phenylbutyrate (NaPB) for the treatment of urea cycle disorders and maple syrup disease. In addition, Relief’s recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH provide Relief with a diverse portfolio of commercialized and development-phase programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbol RLFTF. For more information, visit Follow us on LinkedIn.

Jack weinstein
Financial Director and Treasurer

Rx communication group
Michael miller
+ 1-917-633-6086

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements involve certain risks, uncertainties and other known and unknown factors, in particular (i) whether InveniAI will provide RELIEF THERAPEUTICS Holding SA with drug candidates that can be successfully developed by RELIEF THERAPEUTICS Holding SA, (ii) if RELIEF THERAPEUTICS Holding SA will succeed in developing and ultimately commercializing any drug candidate identified by InveniAI, and (iii) the risks discussed in the press releases and files of RELIEF THERAPEUTICS Holding SA with SIX, which could lead to actual results, financial situation, performances or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from the future results, performances or achievements expressed or implied by these forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication on this date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

THE SOURCE: Relief Therapeutics Holdings AG

See the source version on

Leave a Comment